



Quarterly Factsheet as at 31st Dec 2025

Investment Strategy Objectives

The AIM Portfolio is designed for clients wishing to invest in a portfolio of AIM Market listed products that in qualifying for Business Property Relief should be exempt from Inheritance Tax, if held for more than a 2 year period. AIM stocks can be much more volatile than both large and mid cap company shares and as such are categorised as Higher Risk.

It is strongly recommended that investors read the James Brearley AIM Portfolio Service Brochure for further information on this portfolio.

The JB AIM Portfolio is benchmarked against the Numis Alternatives Market Index.



OUR INVESTMENT MANAGEMENT SERVICE HAS ACHIEVED A DEFAQTO 5 STAR RATING.

Performance

Cumulative Total Return Performance

INDEX	1y Total Return %	3y Total Return %	5y Total Return %
JB AIM Portfolio*	-3.11	-5.53	-25.87
Numis Alternative Market Index	6.28	-5.16	-29.66
Cboe UK All Companies Index	24.38	47.12	76.96

Discrete 1 Year Total Return Performance

INDEX	Dec 2025 Total Return %	Dec 2024 Total Return %	Dec 2023 Total Return %	Dec 2022 Total Return %	Dec 2021 Total Return %
JB AIM Portfolio*	-3.11	-5.50	1.13	-31.09	16.03
Numis Alternative Market Index	6.28	-3.85	3.17	-31.68	17.09
Cboe UK All Companies Index	24.38	9.88	7.65	1.92	18.02


Source: FE Analytics. All performance figures shown are Total Return. As at 31st Dec 2025

*Source: James Brearley

Important Information

Investing in stockmarket based investments may not be right for all investors. You should consider carefully and/or seek professional guidance before investing. Please remember that past performance should not be seen as a guide to future performance. The value of an investment and any income from it can fall as well as rise as a result of market and currency movement and you may not get back the amount originally invested.

JB UK AIM Portfolio (Total Return) - 31st Dec 2020 - 31st Dec 2025



Source: FE Analytics and James Brearley

Sector Summary (31/12/2025)



Alternative Investment Market (AIM)

Overall Risk Summary (31/12/2025)



High Risk

Current Portfolio (31/12/2025)

	Weighting %	Yield %
ADVANCED MEDICAL SOLUTIONS GROUP	4.00%	1.21%
ALUMASC GROUP	4.00%	4.42%
BRICKABILITY GROUP	4.00%	6.43%
DOTDIGITAL GROUP	4.00%	1.88%
FEVERTREE DRINKS	4.00%	2.08%
FOCUSRITE	4.00%	1.67%
FONIX MOBILE	4.00%	5.27%
FRP ADVISORY GROUP	4.00%	4.09%
GLOBALDATA	4.00%	1.06%
IMPAX ASSET MANAGEMENT GROUP	4.00%	8.11%
JAMES HALSTEAD	4.00%	6.31%
JET2	4.00%	1.19%
M.P EVANS GROUP	4.00%	4.48%
NICHOLS	4.00%	3.30%
QUARTIX TECHNOLOGIES	4.00%	3.25%
RENEW HOLDINGS	4.00%	2.21%
ROSEBANK INDUSTRIES	4.00%	0.00%
RWS HOLDINGS PLC	4.00%	7.39%
YU GROUP	4.00%	3.89%
AB DYNAMICS	2.00%	0.68%
ANIMALCARE	2.00%	2.08%
ARGENTEX GROUP	0.15%	0.00%
BIOVENTIX	2.00%	8.33%
CRANEWARE	3.85%	1.66%
EVERPLAY GROUP	2.00%	1.11%
KITWAVE GROUP	2.00%	5.40%
MHA GROUP	2.00%	0.00%
PROPERTY FRANCHISE GROUP	2.00%	4.37%
RAMSDENS HOLDINGS	2.00%	3.72%
TRISTEL	2.00%	3.94%
YOUGOV	2.00%	3.37%
INVESTMENT TOTAL	100%	3.33%

Recent Changes

In the 4th quarter, CVS Group and Idox were sold and replaced by Rosebank Industries and MHA Group.

Important Disclosure

This document is not, and should not be construed as, an offer to sell or solicitation of an offer to buy any securities. This information and opinions contained in this document have been compiled in good faith from sources believed to be reliable, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. All opinions and estimates contained in this document constitute our judgement as of the date of this document and are subject to change without notice. No responsibility is taken for any losses that may be incurred by clients acting upon the information.

This document has been prepared with all reasonable care on the basis of publicly available information and sources that are believed to be reliable. The investments mentioned in this document may not be suitable for all recipients or be appropriate for their individual circumstances. The information contained in the document is published for the assistance of recipients, but is not to be relied upon as authoritative or taken in substitution for the exercise of judgement by any recipient.

Any information about our model portfolios and the proposed portfolio structure is correct at the stated date of this document but may be subject to change. Although the model portfolios are representative of a client's individual portfolio the asset allocation of and the investments held in a client's individual portfolio may differ. Total return performance has been calculated by adding in the projected income from the other positions being re-invested on a quarterly basis as part of a general re-balance exercise.

The returns achieved by a client may be lower than the returns shown in this document. The returns shown in this document do not take into account any fee or payment made to a third party such as a financial adviser's fee.

Investing in stock market based investments may not be right for all investors. You should consider carefully and/or seek professional guidance before investing. Please remember that, all performance data quoted is based on past events, and past performance should not be seen as a guide to future performance. The value of an investment and any income from it can fall as well as rise as a result of market and currency movement and you may not get back the amount originally invested.

This document is issued and approved by James Brearley Ltd, authorised and regulated by the Financial Conduct Authority. FCA Reference Number: 189219